Ackrell Capital Cannabis Company Financial Metrics Table
Summary
The document is a plain financial summary of cannabis companies listed on the Canadian Securities Exchange with no mention of influential actors, misconduct, or controversial transactions. It offers n Provides market cap, revenue, EBITDA, and valuation multiples for dozens of cannabis firms. Includes percentages of stock price below enterprise value. No names of political figures, government agenc
This document is from the House Oversight Committee Releases.
View Source CollectionPersons Referenced (2)
Tags
Related Documents (6)
Cannabis Company Valuation Table from Cowen Report (Feb 2019)
The passage is a plain financial data table listing market metrics for cannabis companies. It contains no references to high‑profile individuals, government actions, or alleged misconduct, offering no Provides enterprise values, revenues, and price metrics for dozens of cannabis firms. Cites Thomson Reuters and Cowen as sources. Dated February 25, 2019, with no contextual commentary.
Ackrell Capital Cannabis OTC Market Valuation Table (2017)
The document is a financial listing of small OTC cannabis companies with market metrics. It contains no references to influential political figures, government agencies, or alleged misconduct, offerin Provides EV multiples and stock price discounts for over 40 cannabis firms. Compiled by Ackrell Capital, a FINRA/SIPC member. Data dated November 30, 2017.
Ackrell Capital report shows modest capital raised by U.S. publicly traded cannabis companies in 2017
The passage provides only aggregate financial data on small, largely unprofitable cannabis firms with no mention of high‑profile individuals, government agencies, or illicit activity. It lacks specifi Only $268 million total equity and debt raised by listed cannabis firms in the 12‑month period endin Most companies had little to no revenue and were not profitable. A single large $317 million finan
Industry analysis of cannabis-derived drug Epidiolex and consumer market opportunities
The passage provides a generic market overview and product strategy for cannabis-derived pharmaceuticals, mentioning no high‑profile individuals, government officials, or illicit financial flows. It l Epidiolex is a CBD‑based drug under FDA review, not yet approved. Approval would require rescheduling under the Controlled Substances Act. Identified market opportunities: health‑wellness brands, e‑c
Directory of Private Cannabis Companies Featured in House Oversight Report
The passage lists several private cannabis producers and their products without mentioning any high‑profile individuals, government agencies, financial transactions, or alleged misconduct. It offers n Level Blends – California cannabis concentrate producer. Lunchbox Alchemy – Oregon cannabis edibles and concentrates maker. LivWell Enlightened Health – Colorado/ Oregon dispensary operator and culti
Ackrell Capital Cannabis Investment Report compares market size to alcohol, coffee, tobacco, and pharmaceuticals
The document is a commercial investment analysis with no mention of political figures, government agencies, or alleged misconduct. It offers no actionable leads for investigations and contains only pu Provides estimated penetration rates and consumer spending for cannabis versus other legal substance Claims U.S. legal cannabis market size aligns with other retail markets. Published by Ackrell Capi
This document was digitized, indexed, and cross-referenced with 1,400+ persons in the Epstein files. 100% free, ad-free, and independent.